Patents by Inventor Beryl Asp

Beryl Asp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods to potentiate intravenous estramustine phosphate
    Patent number: 6849616
    Abstract: Estramustine phosphate is an anti-mitotic chemotherapeutic drug with proven efficacy against cancer. The invention describes methods which potentiate the therapeutic benefit of intravenous estramustine phosphate. The invention provides for intravenous estramustine phosphate to be administered at a high dosage exceeding 1300 mg as a single dose. Efficacious enhancement of estramustine phosphate pharmacokinetics is thereby achieved. Further provided, estramustine phosphate may be intravenously administered for use in combinational regimens with other chemotherapeutic agent. The therapeutic advantages achieved using the intravenous estramustine phosphate formulation are applicable to treatment of a variety of cancers including prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and other cancers.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: February 1, 2005
    Assignee: Pharmacia Italia S.p.A.
    Inventors: Michael S. Kopreski, Beryl Asp, Bo Fredholm, Per-Olv Gunnarsson
  • Method for the treatment of cardiotoxicity induced by antitumor compounds
    Publication number: 20040258692
    Abstract: The present invention relates to a method for treating a cancer, which comprises administering a therapeutically effective amount of trastuzumab alone or in association with an anthracycline to a patient in need thereof, in combination with an amount of dexrazoxane effective to ameliorate cardiotoxicity.
    Type: Application
    Filed: May 17, 2004
    Publication date: December 23, 2004
    Inventors: Beryl Asp, Angela Ogden, Langdon Miller, Arturo Podesta
  • Use of estramustine phosphate in the treatment of bone metastasis
    Publication number: 20040014729
    Abstract: Estramustine phosphate is shown to act as an inhibitor of bone resorption and can thus be used to treat, prevent or alleviate the symptoms of bone metastasis which arise due to said bone resorption.
    Type: Application
    Filed: August 1, 2003
    Publication date: January 22, 2004
    Inventor: Beryl Asp
  • Method for the treatment of cardiotoxicity induced by antitumor compounds
    Publication number: 20030096823
    Abstract: The present invention relates to a method for treating a cancer, which comprises administering a therapeutically effective amount of trastuzumab alone or in association with an anthracycline to a patient in need thereof, in combination with an amount of dexrazoxane effective to ameliorate cardiotoxicity.
    Type: Application
    Filed: November 16, 2001
    Publication date: May 22, 2003
    Inventors: Beryl Asp, Angela Ongden, Langdon Miller, Arturo Podesta
  • Use of estramustine phosphate in the treatment of bone metastasis
    Patent number: 6436913
    Abstract: Estramustine phosphate is shown to act as an inhibitor of bone resorption and can thus be used to treat, prevent or alleviate the symptoms of bone metastasis which arise due to said bone resorption.
    Type: Grant
    Filed: July 25, 2000
    Date of Patent: August 20, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventor: Beryl Asp